GlassScriptPhysician profile
Satiskumar P Patel
NPI 1659303824
$4,258.19
in general payments reported to CMS, 2019-2025
23 companies · $520 in 2025
The $520 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $606 · 2020: $815 · 2021: $860 · 2022: $486 · 2023: $625 · 2024: $346 · 2025: $520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,471 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,471.16 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,342.96 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,133.74 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $367.23 | 2019-2025 | Rybelsus, Ozempic |
| Astellas Pharma US INC | $222.64 | 2019-2024 | Veozah |
| Lilly USA, LLC | $205.79 | 2019-2025 | Mounjaro, Zepbound |
| Inspire Medical Systems, INC. | $151.79 | 2025 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $119.60 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $115.28 | 2019-2023 | Belsomra |
| Pfizer INC. | $88.97 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $84.98 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.55 | 2019 | |
| Dexcom, INC. | $47.86 | 2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $44.57 | 2020-2021 | |
| Abbott Laboratories | $43.96 | 2022-2023 | Freestyle Libre 3 |
| Antares Pharma, INC. | $34.66 | 2022-2023 | Xyosted, Nocdurna, Tlando |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $31.18 | 2020-2023 | Repatha |
| Sumitomo Pharma America, INC. | $29.23 | 2025 | Gemtesa |
| Halozyme INC | $26.57 | 2023 | |
| Almatica Pharma LLC | $24.48 | 2021 | |
| Janssen Pharmaceuticals, INC | $22.60 | 2019 | |
| Sunovion Pharmaceuticals INC. | $22.51 | 2022 | |
| Boston Scientific Corporation | $20.02 | 2021 | |
| Alk-Abello, INC | $13.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Satiskumar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.